Clinical trials: SARS-CoV2
Suspected or Confirmed COVID-19
NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients
This open-label, randomized, and controlled clinical trial aims to determine the feasibility and effectiveness of using NBT-NM108, a novel botanical-based fixed-combination drug, to modulate the gut microbiota and treat…
- Trial name
- COVGUT20 (NCT04540406)
- Testing
- NBT-NM108, Usual Care Only
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Notitia Biotechnologies Company
SARS-CoV-2 Infection
A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19
The purpose of this post marketing observational study is to learn about the safety and effects of the commercial medicine (called PAXLOVID) for the treatment of COVID-19.
- Trial name
- NCT05263908
- Testing
- nirmatrelvir / ritonavir
- Where
- Japan
- Volunteers
- 3,346 people
- Sponsor
- Pfizer
Covid19
A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19
This study aims to investigate the potential antiviral efficacy and safety of a novel formulation of Niclosamide; a well-known antihelmintic agent, together with an established COVID-19 treatment regimen in patients.
- Trial name
- NICLONEX (NCT04558021)
- Testing
- Niclosamide suspension
- Where
- 8 sites in Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Imuneks Farma ilac San. Tic. A.S.
COVID-19
A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19
This is a phase 1b, randomized, double-blind, positive control trial in healthy adults, intended to evaluate the safety and immunogenicity profile of RQ3013 in healthy adults primed with a two-dose inactivated vaccine 6-9 months…
- Trial name
- NCT05396573
- Testing
- RQ3013, Comirnaty
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.
Coronavirus, COVID
A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
This was a randomized, double-blind, placebo-controlled, 29-day study to assess the efficacy and safety of axatilimab plus standard of care (SOC), compared with placebo plus SOC, in participants with respiratory signs and…
- Conditions
- Coronavirus, COVID, ARDS, Cytokine Storm
- Trial name
- NCT04415073
- Testing
- SNDX-6352
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Syndax Pharmaceuticals
COVID-19
Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine.
IIBR-100 (VSV-ΔG) is a self-propagating live virus vaccine that contains the spike protein of the Wuhan wild-type SARS-CoV-2 virus.
- Trial name
- BRILIFE002 (NCT04990466)
- Testing
- IIBR-100, Active Comparator
- Volunteers
- healthy volunteers welcome
- Sponsor
- NeuroRx, Inc.
Covid19, SARS-CoV-2
A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older
The primary objective of the randomized observer-blinded phase 2b/3 part of this trial is to demonstrate the efficacy of a 2-dose schedule of CVnCoV in the prevention of first episodes of virologically-confirmed cases of COVID-19…
- Trial name
- NCT04652102
- Testing
- CVnCoV, Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination program
- Where
- 46 sites in Argentina, Belgium and 8 more
- Volunteers
- 39,680 people, healthy volunteers welcome
- Sponsor
- CureVac
Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder)
Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection
Randomized, Double Blind, Placebo Controlled, Proof-of-Concept Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection.
- Conditions
- Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder), Covid19
- Trial name
- NCT04705831
- Testing
- Ruconest
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- IMMUNOe Research Centers
SARS-CoV-2 Infection
VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection
This is a clinical study to investigate the safety, tolerability and immunogenicity of a VLA2001 booster vaccination in participants aged 18 years and older. In total approximately 275 participants are planned to be enrolled.
- Trial name
- NCT05364242
- Testing
- VLA2001
- Where
- 4 sites in Netherlands, New Zealand
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Covid19
Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients
This is a randomized, double-blind, placebo-controlled, adaptive two-stage design, human phase 2 study, with add-on treatment arrangement of fluvoxamine or placebo on top of standard of care (base therapy: the actual proposed…
- Trial name
- NCT04718480
- Testing
- Fluvoxamine
- Where
- 4 sites in Hungary
- Volunteers
- 66 people
- Sponsor
- SigmaDrugs Research Ltd.
Sars-cov-2
Treatment of Non-severe Covid-19 Outpatients With Xagrotin, Phase 3
This is an interventional, multi-center, randomized study. Adults with confirmed covid-19 disease not more than 10 days before enrollment date will be recruited (n=1000).
- Trial name
- NCT05222425
- Testing
- Xagrotin, Green tea
- Where
- Iraq
- Volunteers
- 3,000 people
- Sponsor
- Biomad AS
SARS-CoV-2 Infection
Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity and safety profile.
- Trial name
- NCT04636697
- Testing
- Intramuscular injection, Intramuscular vaccine
- Where
- 91 sites in United States, Argentina and 4 more
- Volunteers
- 30,918 people, healthy volunteers welcome
- Sponsor
- Medicago
Coronavirus Disease, SARS-CoV-2 Infection
ImmuneSense™ COVID-19 Cross-Reactivity Study
Adaptive Biotechnologies has developed a clinical test called T-Detect COVID Test that can identify a T-cell response to the SARS-CoV-2 virus, indicating recent or prior infection This study aims to evaluate the potential…
- Trial name
- NCT05112874
- Where
- United States
- Sponsor
- Adaptive Biotechnologies
COVID-19
Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults
This study is a multi-center and open design, phase Ⅳ clinical trial of an inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.The purpose of this study is to evaluate the safety…
- Trial name
- NCT04911790
- Testing
- Experimental Group
- Where
- China
- Volunteers
- 131,650 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
SARS-CoV-2 Infection
To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects
This is a Phase I study that randomized, double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to evaluate Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects.
- Trial name
- NCT05017168
- Testing
- CT-P63
- Where
- Poland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Celltrion
Covid19, Corona Virus Infection
A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit
To evaluate the performance of the FDA EUA authorized Lucira COVID-19 All-In-One Test Kit for the qualitative detection of SARS-CoV-2 virus in nasal swab samples as compared to a known high sensitivity EUA RT-PCR among…
- Trial name
- NCT04720235
- Testing
- Lucira COVID-19 All-In-One test kit
- Where
- United States
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Lucira Health Inc
COVID-19
A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine
This study aims to evaluate the safety and immunogenicity of the preventative vaccine, AdimrSC-2f, in healthy volunteers aged from 20 to 60 years old.
- Trial name
- NCT04522089
- Testing
- AdimrSC-2f
- Where
- Taiwan
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Covid19, Coronavirus
QuadraMune(TM) for Prevention of COVID-19
QuadraMune(TM) is a nutritional supplement which has previously been demonstrated to possess antiinflammatory and immune modulatory activity based on in vitro and pilot in vivo studies.
- Conditions
- Covid19, Coronavirus, SARS-CoV 2
- Trial name
- NCT04421391
- Testing
- QuadraMune(TM)
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Therapeutic Solutions International
Immunocompromised
A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults
The primary objective of the study is to evaluate the effect of casirivimab+imdevimab, compared with placebo, in preventing symptomatic SARS-CoV-2 infection in immunocompromised participants.
- Trial name
- NCT05074433
- Testing
- casirivimab+imdevimab
- Where
- 67 sites in United States, Mexico
- Volunteers
- 66 people
- Sponsor
- Regeneron Pharmaceuticals
Prevention of COVID-19, Safety and Efficacy
A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19
A randomized, double-blind, placebo-controlled international multicenter clinical trial design will be adopted. A total of 29,000 subjects aged 18 years and above are planned to be recruited, including 750 subjects aged 18-59…
- Trial name
- NCT04646590
- Testing
- Recombinant new coronavirus vaccine (CHO cell) group
- Where
- 18 sites in China, Ecuador and 3 more
- Volunteers
- 28,904 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.